Finasteride vs GHK-Cu
FDA Approved vs Well Studied
compatible GHK-Cu supports wound healing and may promote hair follicle health through copper peptide activity. No known negative interactions with finasteride.
Molecular Data
Finasteride GHK-Cu
Weight 372.54 Da 404.96 Da
Half-life 6-8 hours (DHT suppression persists ~24 hours) 0.5-2 hours
Chain — 3 amino acids
Type Synthetic 4-azasteroid compound Copper tripeptide
Key Benefits
Finasteride
01 Reduces scalp DHT by approximately 66% at 1mg daily
02 Slows or stops hair loss progression in roughly 90% of men
03 Produces visible hair regrowth in approximately 48% of men within 1-2 years
04 FDA-approved with over 25 years of clinical use and long-term safety data
05 Convenient once-daily oral dosing with no injections required
06 Well-characterized side effect profile with low incidence of adverse events
07 Can be combined with minoxidil for enhanced efficacy
GHK-Cu
01 Enhanced collagen production (70% increase in type I and III)
02 Improved skin elasticity
03 Reduced fine lines and wrinkles
04 Accelerated wound healing
05 Hair growth stimulation
06 Antioxidant protection
Dosing Protocols
Finasteride
1mg/day (hair loss) or 5mg/day (BPH) / Once daily
GHK-Cu
0.5-2% topical or 1-3mg injectable / 1-2x daily
Systemic anti-aging 1-2mg 1x daily
Enhanced regeneration 2-3mg 1-2x daily
Side Effects
Finasteride
Decreased libido (reported in 1.8% of men in clinical trials vs 1.3% placebo)
Erectile dysfunction (reported in 1.3% vs 0.7% placebo)
Decreased ejaculate volume (reported in 0.8% vs 0.4% placebo)
GHK-Cu
Mild skin irritation initially (usually resolves)
Increased photosensitivity
Contraindications
Women who are pregnant or may become pregnant (finasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling crushed tablets poses a risk)
Women who are breastfeeding
Known hypersensitivity to finasteride or any component of the formulation
Severe hepatic impairment (finasteride is metabolized by the liver)
Pediatric patients (not indicated for use in children)
Known copper sensitivity or Wilson's disease
Active skin infections at application site
Pregnancy or breastfeeding (injectable)
Research Evidence
Finasteride GHK-Cu
Status FDA Approved Well Studied
References 5 studies 5 studies
Latest — July 2025
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.